down arrow

Navidea Biopharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US63937X2027
USD
0.00
0.00 (0.00%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.05
Valuation
Technical
Day's Volume

CASH

10.93 k

Shareholding (Dec 2023)

FII

0.02%

Held by 3 FIIs

DII

99.18%

Held by 1 DIIs

Promoter

0.00%

How big is Navidea Biopharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Navidea Biopharmaceuticals, Inc. has a market capitalization of 0.07 million, with net sales of 0.00 million and a consolidated net profit of -8.61 million over the latest four quarters. As of Dec'22, shareholder's funds were -8.44 million, and total assets were 4.37 million.

Market Cap: As of Jun 18, Navidea Biopharmaceuticals, Inc. has a market capitalization of 0.07 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Navidea Biopharmaceuticals, Inc. reported net sales of 0.00 million and a consolidated net profit of -8.61 million.<BR><BR>Balance Sheet Snapshot: As of Dec'22, the company's shareholder's funds stood at -8.44 million, while total assets were reported at 4.37 million.

Read More

What does Navidea Biopharmaceuticals, Inc. do?

22-Jun-2025

Navidea Biopharmaceuticals, Inc. is a micro-cap biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. As of September 2023, it reported a net profit loss of $2 million and has a market cap of $0.07 million.

Overview: <BR>Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Sep 2023) <BR>Market-cap: USD 0.07 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.80 <BR>Return on Equity: 294.84% <BR>Price to Book: -0.02<BR><BR>Contact Details: <BR>Address: 4995 Bradenton Ave Ste 240, DUBLIN OH: 43017-3552 <BR>Tel: ['1 614 7937500', '1 614 9737490'] <BR>Fax: 1 614 7937520 <BR>Website: https://www.navidea.com/

Read More

Who are in the management team of Navidea Biopharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Navidea Biopharmaceuticals, Inc. includes Independent Chairman Mr. Y. Michael Rice, Directors Mr. Malcolm Witter, Dr. Claudine Bruck, Mr. Adam Cutler, and Dr. S. Kathryn Rouan, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Navidea Biopharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Y. Michael Rice, who serves as the Independent Chairman of the Board.<BR>- Mr. Malcolm Witter, who is a Director.<BR>- Dr. Claudine Bruck, who holds the position of Independent Director.<BR>- Mr. Adam Cutler, also an Independent Director.<BR>- Dr. S. Kathryn Rouan, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Navidea Biopharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

Navidea Biopharmaceuticals, Inc. is currently assessed as overvalued with significant financial concerns, reflected in its negative price-to-book value and poor market performance, despite a misleadingly high return on capital employed.

As of 8 August 2019, the valuation grade for Navidea Biopharmaceuticals, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently assessed as overvalued, primarily due to its negative price-to-book value of -0.02 and an EV to EBITDA ratio of 0.25, which suggests that the company is not generating sufficient earnings relative to its enterprise value. Additionally, the return on capital employed (ROCE) is exceptionally high at 173.19%, but this figure is misleading given the company's overall financial instability.<BR><BR>In comparison with peers, Navidea's valuation metrics are concerning. For instance, BioRestorative Therapies, Inc. has a worse EV to EBITDA ratio of -0.3148, while Ekso Bionics Holdings, Inc. shows a risky valuation with an EV to EBITDA of -0.7257. The stock has significantly underperformed against the S&P 500 over various periods, notably a 71.43% decline in the past week, reinforcing the notion that it is overvalued given its current financial state and market performance.

Read More

Is Navidea Biopharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of June 3, 2025, Navidea Biopharmaceuticals, Inc. is in a mildly bearish trend, indicated by a bearish MACD and moving averages, despite bullish weekly and monthly RSI readings, with a significant 1-year return of -90.0% compared to the S&P 500's 17.14%.

As of 3 June 2025, the technical trend for Navidea Biopharmaceuticals, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and mildly bearish moving averages on the daily timeframe. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish trend. Notably, the stock has experienced significant declines, with a 1-year return of -90.0% compared to the S&P 500's 17.14%, indicating substantial underperformance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.80

stock-summary
Return on Equity

294.84%

stock-summary
Price to Book

-0.02

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-80.0%
0%
-80.0%
6 Months
-85.71%
0%
-85.71%
1 Year
0%
0%
0.0%
2 Years
-99.86%
0%
-99.86%
3 Years
-99.96%
0%
-99.96%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Navidea Biopharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Navidea Biopharmaceuticals, Inc. technically bullish or bearish?

As of 3 June 2025, the technical trend for Navidea Biopharmaceuticals, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and mildly bearish moving averages on the daily timeframe. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish trend. Notably, the stock has experienced significant declines, with a 1-year return of -90.0% compared to the S&P 500's 17.14%, indicating substantial underperformance....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
3.11%
EBIT to Interest (avg)
-11.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.80
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.38%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.02
EV to EBIT
0.25
EV to EBITDA
0.25
EV to Capital Employed
0.43
EV to Sales
-2.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
173.19%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (0.8%)

Foreign Institutions

Held by 3 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Sep 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 59.65% vs -137.50% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-4.90",
          "chgp": "57.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-5.70",
          "chgp": "59.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-658,700.20%",
          "chgp": "65,870.02%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -80.00% vs -44.44% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -29.91% vs -9.35% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.80",
          "val2": "-11.90",
          "chgp": "-15.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.20",
          "val2": "-11.70",
          "chgp": "-29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-214,020.80%",
          "val2": "-22,690.70%",
          "chgp": "-19,133.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.10
-4.90
57.14%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.30
-5.70
59.65%
Operating Profit Margin (Excl OI)
0.00%
-658,700.20%
65,870.02%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 59.65% vs -137.50% in Sep 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.10
0.50
-80.00%
Operating Profit (PBDIT) excl Other Income
-13.80
-11.90
-15.97%
Interest
1.10
0.00
Exceptional Items
0.00
0.40
-100.00%
Consolidate Net Profit
-15.20
-11.70
-29.91%
Operating Profit Margin (Excl OI)
-214,020.80%
-22,690.70%
-19,133.01%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -80.00% vs -44.44% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -29.91% vs -9.35% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Navidea Biopharmaceuticals, Inc. stock-summary
stock-summary
Navidea Biopharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.
Company Coordinates stock-summary
Company Details
4995 Bradenton Ave Ste 240 , DUBLIN OH : 43017-3552
stock-summary
Tel: 1 614 79375001 614 9737490
stock-summary
https://www.navidea.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."